Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | FDPS | P14324 | 15/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136428 | 0.98 | CA12 (0.47) | CA12CA1CA2CA9FDPS | |
| SCHEMBL9298865 | 0.96 | CA12 (0.49) | CA12CA1CA2CA9FDPS | |
| SCHEMBL6222263 | 0.96 | CA12 (0.49) | CA12CA1CA2CA9FDPS | |
| SCHEMBL9615006 | 0.94 | FDPS (0.45) | CA12CA1CA2CA9FDPS | |
| SCHEMBL18161694 | 0.86 | FDPS (0.40) | CA12CA1CA2CA9FDPS | |
| SCHEMBL18161709 | 0.86 | FDPS (0.40) | CA12CA1CA2CA9FDPS | |
| SCHEMBL3067217 | 0.85 | CA12 (0.41) | CA12CA1CA2CA9FDPS | |
| SCHEMBL9082973 | 0.85 | FDPS (0.47) | CA12CA1CA2CA9FDPS | |
| SCHEMBL18161706 | 0.83 | FDPS (0.44) | CA12CA1CA2CA9FDPS | |
| SCHEMBL18161689 | 0.83 | FDPS (0.44) | CA12CA1CA2CA9FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011163389-A2 | METHOD FOR INDUCING FAT LOSS IN MAMMALS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-12-29 | — | — | WO | claimed |
| US-7820197-B2 | Percutaneous preparations | ASTELLAS PHARMA INC. (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20100055159-A1 | PERCUTANEOUS PREPARATIONS | TSUJI YASUHIRO | 2010-03-04 | — | — | US | disclosed |
| US-20050106186-A1 | Percutaneous preparations | KYUKYU PHARMACEUTICAL CO., LTD. (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1475095-A1 | PERCUTANEOUS PREPARATIONS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055159-A1 | PERCUTANEOUS PREPARATIONS | FFAR1, FFAR2, PPARD | CA12 2137/4885CA1 3883/4885CA2 3211/4885 |
| US-20050106186-A1 | Percutaneous preparations | FFAR1, FFAR2, PPARD | CA12 2137/4885CA1 3883/4885CA2 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.